A Phase 2/3 interventional study of Leukocyte-rich platelet-rich plasma and Leukocyte-poor platelet-rich plasma in Osteo Arthritis Knee, sponsored by Queen Savang Vadhana Memorial Hospital, Thailand. Completed at 1 site in Thailand. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-02-21.
Sponsored by Queen Savang Vadhana Memorial Hospital, Thailand · Phase 2/3, Interventional, and Treatment
To compare the efficacy of intraarticular knee injection between leukocyte-rich and leukocyte-poor platelet-rich plasma in knee osteoarthritis treatment
Participants were randomized into 3 groups (leukocyte-rich platelet-rich plasma (LR-PRP), leukocyte-poor platelet-rich plasma (LP-PRP), and Corticosteroid (CS)). The primary outcome of this study is The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and was measured pre-treatment and post-treatment at follow-up at 1, 3, and 6 months
4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.
This study's enrollment of 93 is above the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →Queen Savang Vadhana Memorial Hospital, Thailand is the lead sponsor of 29 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Leukocyte-rich PRP: Centrifuge at 300 G for 5 min, separate the plasma and buffy coat layers, and then centrifuge at 700 G for 17 min with calcium chloride at the ratio of 1:5 to PRP by volume.
Drug: Leukocyte-poor platelet-rich plasma · Drug: Corticosteroid
Leukocyte-poor PRP: Centrifuge at 123 G for 15 min, separate the plasma and buffy coat layers, and then centrifuge at 448 G for 10 min. Calcium chloride was added 1:5 to PRP by volume.
Drug: Leukocyte-rich platelet-rich plasma · Drug: Corticosteroid
Corticosteroid: 1 ml of triamcinolone acetonide (40mg/ml) mixed with 0.9% NaCl to a total volume of 4 ml.
Drug: Leukocyte-rich platelet-rich plasma · Drug: Leukocyte-poor platelet-rich plasma
Intra-articular knee injection
Also known as: LRPRP
Intra-articular knee injection
Also known as: LPPRP
Intra-articular knee injection
Also known as: CS
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
a self-administered questionnaire consisting of 24 items divided into 3 subscales Pain (5 items) Stiffness (2 items) Physical Function (17 items)
Time frame: 6 months
VAS pain
total of 10 score
Time frame: 6 months
the time up and go test
unit: second
Time frame: 6 months
30-second chair stand test
unit second
Time frame: 6 months
Plan to share: No
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Savang Vadhana Memorial Hospital, Thailand